埃坦尼塞普特用于治疗牛皮性关节炎和牛皮:一项随机试验
相关实验视频
Updated: Jul 23, 2026

11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
1Minor and James Medical, Seattle, WA 98104, USA. pmease@u.washington.edu
Lancet (London, England)
|September 6, 2000
概括
在12周的试验中,Etanercept显著改善了牛皮关节炎和牛皮症状. 这种瘤亡因子抑制剂为患有这些炎症状况的患者提供了新的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
背景情况:
- 瘤亡因子 (TNF) 参与了牛皮关节炎和牛皮的发病.
- 作为TNF抑制剂的Etanercept在类风湿性关节炎中已经显示出有效性.
- 关节和皮肤中TNF度的增加表明,乙太是治疗牛皮的潜在治疗标.
研究的目的:
- 评估埃坦塞普特在患有牛皮性关节炎和牛皮的患者中的疗效和安全性.
- 评估乙太对牛皮关节炎反应标准 (PsARC) 和美国风湿病学会改善标准 (ACR20) 的影响.
- 为了测量乙太在改善牛皮病严重性的有效性,使用牛皮病区域和严重性指数 (PASI) 和目标病变.
主要方法:
- 一项为期12周的随机,双盲,安慰剂控制的研究.
- 60名患有牛皮关节炎和牛皮的患者接受了乙坦塞普特 (25毫克每周两次进行皮下注射) 或安慰剂.
- 使用PsARC,ACR20,PASI和目标病变评估来评估有效性.
主要成果:
- 与安慰剂相比,Etanercept治疗导致PsARC (87%vs. 23%) 和ACR20 (73%vs. 13%) 的实现率显著提高.
- 与安慰剂 (p=0.015) 相比,接受乙太治疗的患者中,较大比例的患者 (26%) 在PASI中实现了75%的改善.
- 乙坦塞普的PASI改善的中位数为46%与安慰剂的9%,而中位数的目标病变改善为50%与0%.
结论:
- 乙南塞普特在治疗牛皮关节炎和牛皮症状方面表现出显著的疗效.
- 这项研究支持以太作为一种新的,有效的治疗方案来治疗这些疾病.
- 在研究群体中,etanercept的耐受性很好.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

